Starting testosterone replacement therapy without a comprehensive baseline is like driving without a dashboard. You won't know if the treatment is working, whether it's causing harm, or what your body looked like before you changed it. BSSM guidelines require 16+ baseline markers. Many online TRT clinics test fewer than half. A comprehensive panel like the TrueVitals Ultimate covers every marker your prescriber needs across 114 biomarkers — the deepest TRT baseline available for £349.
Once you start TRT, your hypothalamic-pituitary-gonadal (HPG) axis shuts down. Your body stops producing testosterone naturally because exogenous testosterone suppresses LH and FSH. Your pre-TRT LH, FSH, and natural testosterone levels become irrecoverable data. If you never measured them, they're gone.
This matters for three reasons. First, if you decide to stop TRT, recovery depends on understanding your pre-treatment baseline. Second, your prescriber needs pre-treatment haematocrit, PSA, lipids, and liver function to monitor for adverse effects versus pre-existing conditions. Third, if your symptoms don't improve on TRT, your baseline data helps identify whether testosterone was actually the problem or whether thyroid, metabolic, or other hormonal issues were driving your symptoms all along.
A comprehensive baseline is not a luxury. It is clinical due diligence. Any clinic that starts TRT without one is prioritising speed over safety.
The British Society for Sexual Medicine (BSSM) and Endocrine Society both recommend a comprehensive baseline. This is the minimum clinical standard. Many clinics fall short of it.
UK guidelines require two separate blood tests showing low total testosterone, both taken before 10am. Testosterone peaks in the early morning and declines throughout the day. A single afternoon reading can underestimate your true level by 20 to 30%. Two confirmed low readings rule out transient suppression from poor sleep, illness, stress, alcohol, or recent training.
Total testosterone alone doesn't tell the full story. SHBG determines how much is biologically available. LH and FSH distinguish primary hypogonadism (testicular failure: high LH, low T) from secondary hypogonadism (pituitary problem: low LH, low T). Prolactin screens for pituitary pathology. Oestradiol establishes your pre-TRT aromatisation baseline, which is critical because TRT increases oestradiol conversion. Testosterone guide. ED and prolactin guide.
Haematocrit is the single most critical safety marker. TRT stimulates erythropoiesis. The BSSM recommends reviewing TRT if haematocrit exceeds 0.54 (54%). Polycythaemia occurs in 10 to 25% of patients. Without a baseline, you cannot tell whether elevated haematocrit was pre-existing or treatment-induced. PSA must be checked before starting TRT in all men. TRT does not cause prostate cancer, but it can accelerate undetected existing disease. A baseline PSA protects you. Liver function and lipids establish organ safety baselines that are monitored throughout treatment.
Low testosterone symptoms (fatigue, weight gain, poor mood, low libido, erectile dysfunction, brain fog) overlap with hypothyroidism, insulin resistance, vitamin D deficiency, and chronic cortisol elevation. If one of these is the actual cause, TRT won't fix it. A comprehensive baseline rules them in or out before committing to lifelong hormone replacement. Thyroid guide. Metabolic guide.
The TrueVitals Ultimate panel covers every BSSM baseline marker plus metabolic depth (fasting insulin, HOMA-IR), advanced cardiovascular (ApoB, Lp(a)), immunoglobulins, and tumour markers. 114 biomarkers. Take the report to your TRT prescriber. £349.
The UK's private TRT market has grown rapidly since 2020. Online clinics offer convenience, speed, and direct access to treatment. Many are well-run and clinically responsible. But some prioritise speed of prescription over thoroughness of baseline testing.
A clinic that requires only total testosterone and SHBG before prescribing is cutting corners. Without haematocrit, you can't monitor for polycythaemia. Without PSA, you can't screen for pre-existing prostate issues. Without LH and FSH, you can't distinguish primary from secondary hypogonadism or identify reversible causes. Without oestradiol, you have no baseline for aromatisation monitoring. Without thyroid and metabolic markers, you may be treating the wrong condition.
A comprehensive independent baseline protects you regardless of which clinic prescribes your TRT. You own the data. You can share it with any prescriber, current or future. If you change clinics or need to present your history to an NHS endocrinologist, the baseline is yours.
Red flags in a TRT clinic: prescribing from a single testosterone reading; not requiring a morning blood draw; not testing haematocrit, PSA, or liver function; not offering ongoing monitoring bloods; not asking about family history of prostate cancer or blood clotting disorders. If your clinic does any of these, get an independent baseline before starting treatment.
The baseline is the first test. It is not the last. TRT requires structured, ongoing blood monitoring for as long as you're on treatment.
Many clinicians recommend an early check to catch rapid haematocrit rises and confirm initial dose response. Particularly important for injectable testosterone (Sustanon, enanthate, cypionate).
BSSM recommended recheck. Testosterone trough level, haematocrit, PSA, liver function, oestradiol. Assess whether symptoms are improving and dose is appropriate.
Second recheck. Full panel. By now, testosterone levels should be stable in the mid-to-upper normal range. Haematocrit trend is established. Oestradiol conversion rate is clear.
Annual comprehensive recheck. All baseline markers repeated. Compare against pre-TRT baseline to assess the full impact of treatment on every system.
Ongoing annual monitoring for as long as you're on TRT. BSSM recommends lifetime monitoring. If haematocrit exceeds 0.52, increase frequency regardless of schedule. After any dose change, retest within 4 to 6 weeks.
Timing your blood draw on TRT: for injectable testosterone (Sustanon, enanthate, cypionate), test at trough — the day of your injection, before injecting. This captures your lowest level and ensures your dose maintains adequate levels throughout the cycle. For gels (Testogel, Tostran), test 2 to 6 hours after application. For Nebido (long-acting undecanoate), test mid-cycle.
The TrueVitals report covers every BSSM baseline marker and goes further. The AI cross-system analysis identifies whether your low-testosterone symptoms could be driven by thyroid dysfunction, insulin resistance, cortisol elevation, or nutrient deficiency rather than testosterone alone. If the data suggests TRT is appropriate, the report provides your prescriber with the most comprehensive pre-treatment baseline available. If the data suggests another cause is contributing, the report flags it before you commit to lifelong hormone therapy.
On subsequent tests (3, 6, 12 months), the report compares every marker against your baseline. Haematocrit trending from 0.44 to 0.51 over 6 months is a trajectory your prescriber needs to see. PSA rising from 0.8 to 1.4 warrants closer monitoring. Oestradiol climbing from 80 to 180 pmol/L suggests increased aromatisation. These trends are only visible with serial testing against a comprehensive baseline.
114 biomarkers. Every BSSM baseline marker plus metabolic, cardiovascular, and immune depth. The most comprehensive TRT baseline available. Take the report to your prescriber. £349.
.png)